Telix Pharmaceuticals (NASDAQ:TLX – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued on Friday, Benzinga reports. They presently have a $20.00 price target on the stock. HC Wainwright’s target price indicates a potential upside of 74.67% from the company’s current price.
A number of other analysts also recently issued reports on the stock. Wedbush reaffirmed an “outperform” rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a report on Wednesday. Citigroup restated a “buy” rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. Weiss Ratings upgraded shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, August 21st. Finally, Royal Bank Of Canada upgraded shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $20.50.
Telix Pharmaceuticals Price Performance
Institutional Investors Weigh In On Telix Pharmaceuticals
Several institutional investors and hedge funds have recently modified their holdings of TLX. Hennion & Walsh Asset Management Inc. bought a new stake in shares of Telix Pharmaceuticals during the second quarter valued at approximately $1,731,000. Private Advisor Group LLC raised its position in shares of Telix Pharmaceuticals by 276.3% during the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after buying an additional 128,070 shares during the last quarter. XY Capital Ltd raised its position in shares of Telix Pharmaceuticals by 468.0% during the second quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock valued at $822,000 after buying an additional 58,739 shares during the last quarter. Lazard Asset Management LLC raised its position in shares of Telix Pharmaceuticals by 15.7% during the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock valued at $2,775,000 after buying an additional 39,400 shares during the last quarter. Finally, Bank of America Corp DE raised its position in shares of Telix Pharmaceuticals by 523.8% during the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after buying an additional 8,423 shares during the last quarter.
About Telix Pharmaceuticals
Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.
The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.
Featured Articles
- Five stocks we like better than Telix Pharmaceuticals
- Costco Ends Its Fiscal Year on a High Note, Eyes Big Expansion
- Cracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem
- Oracle’s Force Majeure Notice Exposes a Bigger Problem for the AI Build-Out
- Oil May Be Stronger Than It Looks—And Diamondback Is on Sale
Receive News & Ratings for Telix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
